Many new agents in the pipeline
Another interesting agent is a novel peptide that inhibits the cytokines IL-2, IL-9, and IL-15 (BNZ-1). Signalling of IL-4, IL-7, and IL-21 are unaffected by this peptide, which preserves immunological function (Figure 11). The agent BNZ-1 was effective in a mouse model of immune-mediated hair loss. It led to a reduction of the inflammatory cytokines IL-6, TNF-α and IFNγ and was able to restore hair growth. It proved to be safe in healthy volunteers and a Phase 2 randomised double-blind placebo-controlled dose ranging study in AA is planned in 2018.
“Many pharma companies are now interested in hair disorders and in the hair follicle as a model to study inflammatory pathways, so there is more to come in the next years,” said Prof. Wilma Bergfeld of the Cleveland Clinic
« Restrictive antibiotic use and novel tetracycline Next Article
IL-17C Inhibition in AD and new oral treatments »
Table of Contents: AAD 2018
Psoriasis: an update
What's hot in atopic dermatitis
Pearls of the posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.